Key Clinical Trials Underway for Alopecia Areata Right Now

Lois Levine, MD

In the ever-evolving landscape of clinical trials for hair loss, here are key important studies currently underway. You can learn more about these trials at the Revolutionizing Alopecia Areata, Vitiligo, Eczema (RAVE) Conference, June 8-10 in Chicago, Illinois. **Registration is open - don't miss out!**

A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of IMG-007 in Adult Alopecia Areata (AA) Participants This is a phase 1b/2a, open label study (Inmagene Biopharmaceuticals) to assess the safety, pharmacokinetics, and efficacy of IMG-007 in adult AA participants with 50% or greater scalp hair loss. The study will consist of 2 cohorts with 3 periods: a screening period of up to 5 weeks, a 16-week treatment period, and an 8-week follow- up period. Approximately 6 and 24 participants will be sequentially enrolled into cohort 1 and cohort 2, respectively, to receive 3 intravenous infusions of IMG-007 over 4 weeks. *Estimated study completion date, October 2024.*

Randomized, Double-Blind, Placebo-Controlled Phase 2a, Proof-of-Concept Trial of ADX-914 for the Treatment of Severe Alopecia Areata (SIGNAL-AA) This is a phase IIa, randomized, double-blind, placebo-controlled, multi-center proof-of-concept (POC) study (Q32 Bio Inc) in adult subjects with severe AA. ADX-914 or matching placebo is administered subcutaneously in the clinic setting every 2 weeks for 24 weeks, with follow-up for 12 weeks. Subjects will be randomized 3:1 to drug vs placebo. *Estimated study completion date, December 2024.*

A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata (BRAVE-AA-PEDS) The main purpose of this study (Eli Lilly and Company) is to determine the efficacy and safety of baricitinib for the treatment of severe or very severe alopecia areata in children from 6 years to less than 18 years of age. The study is divided into 4 periods, a 5-week screening period, a 36-week double-blind treatment period, an approximately 2-year long-term extension period, and a 4-week post-treatment follow-up period. *Estimated study completion date, August 2029.*

1565nm Non-ablative Fractional Laser Treat Alopecia Areata The goal of this clinical trial is to evaluate and explore the mechanism of 1565-nm non-ablative fractional laser in the treatment of alopecia areata. Investigators are exploring (a) comparing the secretion of various cells and cytokines around and within hair follicles before and after treatment; (b) determining the Lord Want effector cells with cytokines and demonstrating that they mediate involvement in correcting the immune immunity collapse process. *Estimated study completion date, November 2024.*